Drug Insights

Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Alprazolam

9 February 2024
2 min read

Alprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway. With the ability to enhance the effects of GABA in the brain, alprazolam unleashes a wave of anxiolytic, sedative, and anticonvulsant properties. Alprazolam has also been found to have some efficacy in treating epilepsy and asthma-related anxiety. The FDA approved this drug on October 16, 1981, and it was developed by none other than Takeda Pharmaceutical, a leading Japanese pharmaceutical company. Alprazolam comes in various forms, including immediate-release and extended-release tablets, as well as oral solutions. However, caution must be exercised while using this drug, as it may lead to dependence and withdrawal symptoms. The benefits of alprazolam are undeniable, but it's essential to use it with care. Click on the image below to begin the exploration journey of Alprazolam through the Synapse database!

图形用户界面, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Jaguar Gene Therapy's JAG201 Trials Approved by FDA for Autism and Phelan-McDermid Syndrome Treatment
Latest Hotspot
3 min read
Jaguar Gene Therapy's JAG201 Trials Approved by FDA for Autism and Phelan-McDermid Syndrome Treatment
9 February 2024
Jaguar Gene Therapy has received the green light from the FDA to initiate trials on JAG201 targeting a specific genetic variant associated with Autism Spectrum Disorder and Phelan-McDermid Syndrome.
Read →
The Synapse User's Toolkit: Tips for Searching Venlafaxine
Drug Insights
2 min read
The Synapse User's Toolkit: Tips for Searching Venlafaxine
9 February 2024
Venlafaxine, an SNRI, targets SERT-5 and NET to regulate brain neurotransmitter balance.
Read →
FDA Approves Adaptimmune's Afami-cel Submission for Advanced Synovial Sarcoma with Expedited Review
Latest Hotspot
3 min read
FDA Approves Adaptimmune's Afami-cel Submission for Advanced Synovial Sarcoma with Expedited Review
9 February 2024
Adaptimmune Reveals FDA Approval of Afami-cel Submission for Advanced Synovial Sarcoma Treatment with Expedited Review.
Read →
Unlock the Power of Synapse: A Guide to Searching Dexamethasone
Drug Insights
2 min read
Unlock the Power of Synapse: A Guide to Searching Dexamethasone
9 February 2024
Dexamethasone, a small molecule drug molecule with a glucocorticoid receptor (GR) agonist action, has got all the science enthusiasts' tongues wagging.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.